solute carrier family 13 member 5Genealiases: DEE25 · EIEE25 · INDY · NACT · mIndy
Q-omics provides the consensus-scored SLC13A5 profile across patient tissues and cancer cell-line models. SLC13A5 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SLC13A5 is differentially expressed in 14, with the highest sampling consensus in LIHC. Additionally, SLC13A5 RNA expression shows 13,483 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, LIHC, and TGCT as cancer lineages where SLC13A5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC13A5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC13A5 survival associations across molecular data types. SLC13A5 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC13A5 RNA expression–survival associations across cancer types. High SLC13A5 expression shows unfavorable associations in KIRP, LUAD, STAD, KIRC, SCLC and OV. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SLC13A5 RNA expression.
This table summarizes SLC13A5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SLC13A5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC13A5 shows lower tumor expression in LIHC, UCEC, BRCA and KIRP and higher tumor expression in HNSC and LUSC. The LIHC box plot shows higher SLC13A5 RNA expression in normal versus tumor tissue (log2 FC = −2.040, t-test p < 0.001).
This table shows molecular features associated with SLC13A5 in patient tissues and cancer cell lines. In patient samples, SLC13A5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC13A5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
